A landmark legal settlement will dissolve Purdue Pharma by the end of the week and replace it with a public-focused company, marking a major turn in the long-running opioid crisis litigation.
A federal judge delivered a criminal sentence Tuesday, clearing one of the final legal hurdles tied to the agreement. Consequently, the ruling allows a sweeping deal that resolves thousands of lawsuits to move forward.
Purdue Pharma, the maker of OxyContin, will cease to exist under the plan. Instead, a new entity called Knoa Pharma will take its place and operate with a public health mandate. The opioid crisis has caused more than 900,000 deaths in the United States since 1999. Additionally, it has triggered decades of litigation against drugmakers, distributors and pharmacies.
The company previously reached a deal with the U.S. Department of Justice in 2020. However, that agreement required court approval and additional legal steps before it could take effect. Purdue admitted it lacked safeguards to prevent its drugs from reaching the black market. Furthermore, it acknowledged misleading regulators about its monitoring programs.
The company also admitted it paid doctors through promotional programs to increase prescriptions. In addition, it funded an electronic medical records firm to push opioid-related patient data to physicians.
Only the company faced criminal charges in the case. Meanwhile, no individual executives or owners were prosecuted as part of the agreement. The broader settlement includes USD$8.3 billion in penalties, forfeitures and fines. However, the federal government agreed to collect only USD$225 million under the negotiated terms.
That concession came in exchange for Purdue resolving thousands of civil lawsuits. Consequently, state, local and tribal governments agreed to a unified settlement structure.
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
Read more: Breath Diagnostics completes install of advanced mass spectrometry system
Victims and their families voiced mixed reactions
The deal does not include direct restitution payments from the criminal case itself. Instead, compensation for victims comes through the broader civil settlement framework. Victims and their families voiced mixed reactions during Tuesday’s hearing. Additionally, several people urged the judge to reject the agreement, arguing it falls short of justice.
Some described losing loved ones to opioid overdoses over the past two decades. Meanwhile, others spoke about long struggles with addiction that began with prescribed medications. One mother said she may not receive compensation due to missing decades-old medical records. Consequently, she argued the system still fails many victims.
Others focused on accountability rather than financial compensation. Furthermore, they called for criminal charges against members of the Sackler family, which owns Purdue. Some participants in the settlement process took a different view. In addition, they argued the agreement offers a path toward closure and recovery.
One individual in recovery said moving beyond anger was necessary for personal healing. However, that perspective contrasted sharply with others who continue to seek stronger penalties.
More than 54,000 claimants voted to accept the settlement. Meanwhile, roughly 200 opposed it, reflecting a divided response among victims. The Sackler family has agreed to contribute up to USD$7 billion over 15 years. Additionally, most of that funding will support government programs addressing the opioid crisis.
The extended payment timeline drew scrutiny from the judge during the hearing. Consequently, questions arose about why the family would not pay sooner. Lawyers argued the family must sell assets to generate the funds. However, the judge suggested the structure benefits them by spreading payments over time.
Read more: American lung cancer survivor advocates for low-dose CT scans in new book
Read more: Mayo Clinic study shows robotic tech improves early lung cancer diagnosis
The government will receive majority of settlement funds
The settlement shields Sackler family members from future opioid-related lawsuits. In addition, that protection applies to parties who agree to accept settlement payments.
The family previously received about USD$10.7 billion from Purdue between 2008 and 2018. Furthermore, they said nearly half went toward taxes tied to the business. Individual victims are expected to receive relatively modest payments. Meanwhile, estimates place compensation between roughly USD$8,000 and USD$16,000 per claim.
Government entities will receive the majority of settlement funds. Consequently, officials plan to direct the money toward treatment, prevention and recovery programs. Total opioid-related settlements in the United States now exceed USD$50 billion. Additionally, Purdue’s agreement represents one of the largest single components.
The new company, Knoa Pharma, will operate under state-appointed oversight. In addition, its mandate will focus on addressing addiction and preventing future harm. Millions of internal Purdue documents will become public under the deal. Furthermore, those records could shed light on the company’s past practices and decision-making.
The Sackler family also agreed not to oppose the removal of their name from institutions. Meanwhile, museums and universities have faced pressure to distance themselves from the family. The settlement follows years of legal battles and negotiations. Consequently, parties have already spent more than USD$1 billion on legal and professional fees.
The bankruptcy process played a central role in shaping the outcome. Additionally, it allowed Purdue to consolidate claims and negotiate a global resolution. The agreement could take effect as soon as Friday. Meanwhile, stakeholders continue to debate whether it delivers accountability or simply closes the case.
.
